Surgery Partners (SGRY) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual meeting scheduled for June 6, 2025, to be held virtually at 10:00 a.m. CDT.
Shareholders can access proxy materials and vote online or request paper copies.
Board recommends voting FOR all director nominees and all proposals on the agenda.
Voting matters and shareholder proposals
Election of three Class I directors: John A. Deane, Teresa DeLuca, M.D., and Wayne S. DeVeydt.
Advisory approval of executive compensation for named executive officers.
Approval of the 2025 Omnibus Incentive Plan.
Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2025.
Board of directors and corporate governance
Board recommends a vote FOR all nominated Class I directors.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Surgery Partners
- Payer mix shifts and cost actions drive a conservative outlook and portfolio optimization.SGRY
Barclays 28th Annual Global Healthcare Conference10 Mar 2026 - 2025 margin pressure and net loss shape a cautious 2026 outlook with $530M EBITDA guidance.SGRY
Q4 20253 Mar 2026 - Q2 revenue up 14.2%, Adjusted EBITDA up 18.1%, and 2024 guidance raised on strong growth.SGRY
Q2 20242 Feb 2026 - Q3 revenue and EBITDA grew double digits, led by high acuity cases and acquisitions.SGRY
Q3 202415 Jan 2026 - 2024 revenue up 13.5% and Adjusted EBITDA up 16%, with strong 2025 growth outlook.SGRY
Q4 202415 Dec 2025 - Shareholders will vote on directors, executive pay, a new incentive plan, and auditor ratification.SGRY
Proxy Filing2 Dec 2025 - Q2 2025 revenue and EBITDA rose sharply, guidance reaffirmed, and leverage reduction prioritized.SGRY
Q2 202523 Nov 2025 - Q1 2025 revenue up 8.2% to $776M, Adjusted EBITDA rose, and guidance was reaffirmed.SGRY
Q1 202517 Nov 2025 - Q3 2025 revenue grew 6.6% to $821.5M, with higher EBITDA but a net loss of $22.7M.SGRY
Q3 202511 Nov 2025